Tiapride structure
|
Common Name | Tiapride | ||
|---|---|---|---|---|
| CAS Number | 51012-32-9 | Molecular Weight | 328.42700 | |
| Density | 1.15 g/cm3 | Boiling Point | 498.1ºC at 760 mmHg | |
| Molecular Formula | C15H24N2O4S | Melting Point | 120ºC | |
| MSDS | USA | Flash Point | 255.1ºC | |
Use of TiaprideTiapride, an atypical neuroleptic agent, is a selective dopamine D2-receptor antagonist with little propensity for causing catalepsy and sedation. The IC50 values of Tiapride are 1440, 45.8, >100, and 11.7 μM for D1; D2; D3; D4, respectively[1]. |
| Name | Tiapride hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Tiapride, an atypical neuroleptic agent, is a selective dopamine D2-receptor antagonist with little propensity for causing catalepsy and sedation. The IC50 values of Tiapride are 1440, 45.8, >100, and 11.7 μM for D1; D2; D3; D4, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
D2 Receptor:110-320 nM (IC50) D3 Receptor:180 nM (IC50) |
| References |
| Density | 1.15 g/cm3 |
|---|---|
| Boiling Point | 498.1ºC at 760 mmHg |
| Melting Point | 120ºC |
| Molecular Formula | C15H24N2O4S |
| Molecular Weight | 328.42700 |
| Flash Point | 255.1ºC |
| Exact Mass | 328.14600 |
| PSA | 87.58000 |
| LogP | 2.82590 |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | CV4203800 |
| HS Code | 2924299090 |
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.
Brain 138 , 3221-37, (2015) Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for which there is no effective treatment. Here we provide evidence that activation of serotonergic signalling is... |
|
|
German insurer finds a third of people over 65 take five or more drugs a day.
BMJ 346 , f3905, (2013)
|
|
|
Pharmacological treatment of tic disorders and Tourette Syndrome.
Neuropharmacology 68 , 143-9, (2013) The present review gives an overview of current pharmacological treatment options of tic disorders and Tourette Syndrome (TS). After a short summary on phenomenology, clinical course and comorbid cond... |
| N-[2-(Diethylamino)ethyl]-5-(methylsulfonyl)-o-anisamide hydrochloride |
| N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide |
| EINECS 256-907-9 |
| N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamide |
| MFCD00242730 |